Skip to main content

Security report for auropharma.ca

Auro Pharma Canada · Healthcare · Canada

Medium risk. 7 critical or high findings in Security headers, GDPR outside view and 2 other checks.

Security score

56/100

Risk levelMedium

0–100, higher is better. How it is calculated

Auro Pharma Canada is a subsidiary of Aurobindo Pharma Ltd., a leading global generic pharmaceutical company founded in 1986. The company focuses on research and development, manufacturing of drug intermediates, APIs, and finished formulations, serving the Canadian healthcare market. The website reflects a mature business with a clear market position and a broad product catalog. Technically, the site is built on WordPress with WooCommerce and modern page builders, offering a good user experience and mobile optimization. Security posture is adequate with HTTPS and domain transfer protection, but lacks advanced DNS security and explicit security policies. Privacy compliance is partial, with a privacy policy present but no cookie consent mechanism. Overall, the site is professional and trustworthy with room for improvement in security and privacy transparency.

Scanned

NIS2 and GDPR posture

GDPR outside view
58/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching auropharma.ca

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
77
Security headers
15
Email security
85
DNS health
80
Network security
20
GDPR outside view
58
Average
56

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company operates in the healthcare sector, specifically pharmaceuticals, targeting healthcare professionals and distributors in Canada. It leverages its parent company's global network and regulatory expertise to maintain a competitive edge. The business model is focused on generic drug manufacturing and distribution. The website supports this with detailed product listings and corporate information. Partnerships include related domains hosting policy documents. Growth indicators include a large product catalog and active content updates. The company maintains a consistent brand image and uses standard digital marketing tools.

Security posture

The website uses HTTPS and has domain transfer protection, indicating a baseline security posture. However, DNSSEC is not enabled, which is a recommended security enhancement. No security headers were detected in the HTML content. There is no published security or incident response policy, which limits transparency. The site uses common WordPress plugins, which require regular updates to avoid vulnerabilities. No exposed sensitive data or obvious vulnerabilities were found. Privacy compliance is partial, lacking cookie consent mechanisms. Overall, the security posture is moderate but could be improved with additional controls and transparency.

Recommendations

  1. Enable DNSSEC on the domain to enhance DNS security and prevent spoofing.
  2. Implement and display a cookie consent banner to comply with GDPR and other privacy regulations.
  3. Add security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to harden the website.
  4. Publish a clear security policy and incident response plan accessible to users and partners.
  5. Regularly audit and update WordPress plugins and themes to mitigate vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Auro Pharma Canada
Description
Aurobindo Pharma, founded in 1986, is a leading global generic pharmaceutical company, ranked among India's top 2 by revenue. Auro Pharma is a Canadian subsidiary of Aurobindo Pharma Ltd. The group is vertically integrated with focus on research & development, manufacturing drug intermediates, Active Pharmaceutical Ingredients (API) and finished formulations. It has regulatory expertise, technology and know-how for specialty formulations with a global network and customer centric approach.
Key services
Research & Development, Manufacturing of drug intermediates, Active Pharmaceutical Ingredients (API) production, Finished pharmaceutical formulations
Content quality
good
Branding
consistent

Technology

Stack
WordPress, WooCommerce, Elementor, WPBakery Page Builder, jQuery, Flickity Carousel, Google Tag Manager, Facebook Pixel
Frameworks
WooCommerce, Elementor, WPBakery
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS enabled
  • ClientTransferProhibited domain status
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Analytics, Google Ads, Facebook Pixel
Tracking level
moderate
Privacy practices
basic

Advertising

Tracking pixels
Facebook Pixel, Google Ads
Marketing tools
Facebook Pixel
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a professional pharmaceutical company site with product catalog and corporate information.
  2. No signs of malicious or suspicious content.
  3. Privacy and cookie policies exist but cookie consent mechanism is missing.
  4. No explicit security or incident response policies published.
  5. Use of modern WordPress plugins and frameworks with some performance optimization.
  6. Social media presence limited to LinkedIn.
  7. WHOIS privacy protection used but justified given business type.
Technical notes

Notes

The website is built on WordPress CMS using WooCommerce for e-commerce functionality, enhanced by Elementor and WPBakery page builders. It uses jQuery and Flickity for UI components and integrates Google Analytics, Google Ads, and Facebook Pixel for tracking and marketing. The hosting provider is inferred as Webnames.ca Inc. based on nameservers. Performance is moderate with some optimization potential. Mobile responsiveness is good. SEO is supported by Yoast SEO plugin and structured data (JSON-LD) is implemented for enhanced search engine understanding. Accessibility is basic with some ARIA and screen reader text present but could be improved. Overall, the technical infrastructure is modern and functional but could benefit from performance tuning and enhanced security configurations.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with auropharma.ca. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review auropharma.ca.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.